Tarik Asselah

Summary

Country: France

Publications

  1. ncbi [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]
    Tarik Asselah
    Service d Hépatologie et Unité INSERM CRB3, Universite Paris VII
    Gastroenterol Clin Biol 30:1281-95. 2006
  2. ncbi Interferon free therapy with direct acting antivirals for HCV
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 33:93-104. 2013
  3. ncbi Interferon stimulated genes and hepatitis C virus infection
    Tarik Asselah
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, Paris, France
    J Interferon Cytokine Res 32:557-62. 2012
  4. ncbi Triple therapy with boceprevir or telaprevir for prior HCV non-responders
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, 100 bd du Général Leclerc, 92110 Clichy, France
    Best Pract Res Clin Gastroenterol 26:455-62. 2012
  5. ncbi IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
  6. ncbi Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Liver Int 32:88-102. 2012
  7. ncbi Protease and polymerase inhibitors for the treatment of hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Service d Hepatologie, Hopital Beaujon, Clichy, France
    Liver Int 29:57-67. 2009
  8. ncbi Gene expression and hepatitis C virus infection
    T Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Gut 58:846-58. 2009
  9. ncbi Clevudine: a promising therapy for the treatment of chronic hepatitis B
    Tarik Asselah
    Universite Paris 7 Denis Diderot, Hopital Beaujon, Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U773
    Expert Opin Investig Drugs 17:1963-74. 2008
  10. ncbi [Treatment of chronic hepatitis B]
    T Asselah
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, INSERM U773 CRB3, Université Denis Diderot Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 32:749-68. 2008

Detail Information

Publications72

  1. ncbi [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]
    Tarik Asselah
    Service d Hépatologie et Unité INSERM CRB3, Universite Paris VII
    Gastroenterol Clin Biol 30:1281-95. 2006
    ..In this article we present a comprehensive review of post-transplant hepatitis C virus infection; in particular fibrosis progression and the major challenges according to treatment...
  2. ncbi Interferon free therapy with direct acting antivirals for HCV
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 33:93-104. 2013
    ....
  3. ncbi Interferon stimulated genes and hepatitis C virus infection
    Tarik Asselah
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, Paris, France
    J Interferon Cytokine Res 32:557-62. 2012
    ..Furthermore, improved technology and analytical procedures and the use of large numbers of patients for validation are needed...
  4. ncbi Triple therapy with boceprevir or telaprevir for prior HCV non-responders
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, 100 bd du Général Leclerc, 92110 Clichy, France
    Best Pract Res Clin Gastroenterol 26:455-62. 2012
    ..The aim of this review is to summarize results obtained with Boceprevir or Telaprevir triple therapy for prior HCV experienced patients (non-responders and relapsers)...
  5. ncbi IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
    ..However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity...
  6. ncbi Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Liver Int 32:88-102. 2012
    ..The aim of this review is to summarize mechanisms of action and results obtained with DAAs...
  7. ncbi Protease and polymerase inhibitors for the treatment of hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Service d Hepatologie, Hopital Beaujon, Clichy, France
    Liver Int 29:57-67. 2009
    ..The development of new molecules such as HCV enzyme inhibitors is ongoing. The aim of this review is to summarize results obtained with STATC: protease and polymerase inhibitors...
  8. ncbi Gene expression and hepatitis C virus infection
    T Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Gut 58:846-58. 2009
    ..This paper reviews the published literature on gene expression associated with HCV infection (HCV infection, fibrosis progression), and also according to response to treatment...
  9. ncbi Clevudine: a promising therapy for the treatment of chronic hepatitis B
    Tarik Asselah
    Universite Paris 7 Denis Diderot, Hopital Beaujon, Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U773
    Expert Opin Investig Drugs 17:1963-74. 2008
    ..This article reviews chronic HBV and its therapy options. Specifically, it describes clevudine's potent and sustained antiviral activity as observed in vitro and in vivo...
  10. ncbi [Treatment of chronic hepatitis B]
    T Asselah
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, INSERM U773 CRB3, Université Denis Diderot Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 32:749-68. 2008
    ..More potent drugs and new combinations as well as understanding the mechanisms of viral resistance should be evaluated to improve the efficacy of treatment...
  11. ncbi Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Liver Int 30:1259-69. 2010
    ..The goal of this review is to present the mechanisms of non-response, to overcome it and to identify factors that can help to predict the response to anti-HCV therapy...
  12. ncbi In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
    ..This lack of gene induction may be explained by the inhibiting action of HCV per se (as suggested by in vitro studies) and/or by our finding of the localized nature of hepatocyte ER stress...
  13. ncbi New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Liver Int 31:68-77. 2011
    ..There is ongoing development of new molecules such as HCV enzyme inhibitors. The aim of this review is to summarize the results obtained with DAAs: protease and polymerase inhibitors...
  14. ncbi [Treatment of chronic hepatitis B]
    Tarik Asselah
    Hopital Beaujon, Service d Hepatologie, AP HP, 92110 Clichy
    Rev Prat 61:45-51. 2011
    ..Telbivudine is more potent and has a lower rate of resistance than lamivudine but the resistance rate is significantly higher than other approved drugs. Tenofovir has a potent antiviral effect with a good resistance profile...
  15. ncbi A sprint to increase response to HCV treatment: expectancies but caution
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    J Hepatol 55:1154-8. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  16. ncbi Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
    T Asselah
    Service d Hepatologie, Pôle des Maladies de l Appareil Digestif and INSERM U773, CRB3, University of Paris VII, AP HP Beaujon Hospital, Clichy, France
    Gut 57:516-24. 2008
    ..Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC...
  17. ncbi Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  18. ncbi Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
    ..Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients...
  19. ncbi Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin
    Valerie Paradis
    Service d anatomie pathologie, Hopital Beaujon, and CNRS UMR 8149, Clichy, France
    Gastroenterology 130:2189-97. 2006
    ..We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response...
  20. ncbi Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..CONCLUSION: Early serum HBsAg drop has high predictive values of SVR to PEG-IFN in HBeAg-negative CHB patients. Serum quantitative HBsAg may be a useful tool to optimize the management of PEG-IFN therapy in these patients...
  21. ncbi Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    Institut National de la Sante et de la Recherche Medicale, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Paris, France
    Hepatology 51:1122-6. 2010
    ..7%), is as relevant as after 24 weeks to predict SVR and make decisions on the management of treated patients, suggesting a new definition for SVR...
  22. ncbi High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  23. ncbi Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  24. ncbi Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  25. ncbi Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy
    Sarah Maylin
    Service de Microbiologie, Universite Paris VII, Faculté de Médecine Denis Diderot, Hopital Bichat, Paris, France
    J Clin Virol 53:43-7. 2012
    ..Correlation between hepatic HCV-RNA and serum HCV-RNA, severity of liver disease and response to therapy is poorly known...
  26. ncbi Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C
    Tarik Asselah
    Service d hépatologie and INSERM CRB3, AP HP Hôpital Beaujon, University of Paris VII, Paris, France
    Gastroenterology 129:2064-75. 2005
    ....
  27. ncbi Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study
    Pierre Bedossa
    Service d Anatomie Pathologique, CNRS UMR 8149, Clichy, France
    Hepatology 46:380-7. 2007
    ..NASH is more common in genotype 3 and is not associated with metabolic dysfunctions in this subgroup, suggesting that NASH may complicate steatosis in CHC irrespective of etiology of steatosis...
  28. ncbi Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C
    David Saadoun
    , , Paris, France
    Hepatology 43:1337-45. 2006
    ..001), and steatosis higher than 10% (P = .04). In conclusion, our study shows an independent association between cryoglobulin and steatosis as well as advanced fibrosis...
  29. ncbi Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  30. ncbi Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue
    Tarik Asselah
    Service d Hépatologie and Institut National de la Santé et de la Recherche Médicale INSERM U733, CRB3, Universite Paris Diderot, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Clichy, France
    Hepatology 48:953-62. 2008
    ....
  31. ncbi High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  32. ncbi Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C
    Ana Carolina Cardoso
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, APHP, University of Paris 7, Clichy, France
    Liver Int 32:612-21. 2012
    ..A secondary analysis was performed to assess whether or not alanine aminotransferase (ALT) levels would impact on the accuracy of TE...
  33. ncbi Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma
    Chiara Viola
    , INSERM CRB3, University of Paris VII, , Beaujon, Clichy 92 110, France
    World J Gastroenterol 12:4911-3. 2006
    ..Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater than that of those who do not receive immunosuppressive therapy...
  34. ncbi Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
    Tarik Asselah
    Service d Hépatologie and INSERM U773, CRB3, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Semin Liver Dis 27:13-27. 2007
    ..This article reviews genetic, genomic, and proteomic aspects associated with the natural history of HCV infection (i.e., viral clearance, fibrosis progression) and the response to therapy...
  35. ncbi Interferon therapy for chronic hepatitis B
    Tarik Asselah
    Service d Hepatologie, INSERM U773, CRB3, University of Paris VII, Hopital Beaujon, 92110 Clichy, France
    Clin Liver Dis 11:839-49, viii. 2007
    ..This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B...
  36. ncbi Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection
    Ivan Bieche
    Laboratoire de Génétique Moléculaire UPRES EA 3618, Faculte des Sciences Pharmaceutiques et Biologiques, Universite Paris V, Paris, France
    Virology 332:130-44. 2005
    ..Some of the genes identified here could form the basis for new approaches aimed at refining IFN-based therapies for chronic HCV infection...
  37. ncbi Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy
    Liana Codes
    Service d Hepatologie, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Gut 56:390-5. 2007
    ..The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT)...
  38. ncbi SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules
    Valerie Paradis
    Department of Pathology, INSERM U773, the Serviced Hépatologie, Beaujon Hospital, AP HP, University Paris Diderot, Paris, France
    Am J Pathol 177:1791-7. 2010
    ..SCG10 may represent a potential molecular target for anti-fibrosis therapies...
  39. ncbi Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection
    Pierre-Emmanuel Rautou
    , University of Paris VII, , Clichy, France
    Eur J Gastroenterol Hepatol 18:1019-22. 2006
    ..We conclude that the combination of PegIFN plus ribavirin may induce suppression of both viral infections...
  40. ncbi Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT
    Maxime Ronot
    Unit for Training and Research in Medicine, Universite Paris 7 Denis Diderot, Paris, France
    Radiology 256:135-42. 2010
    ..To prospectively assess the utility of perfusion computed tomography (CT) for differentiating minimal from intermediate fibrosis in treatment-naïve patients with chronic hepatitis C virus (HCV) infection...
  41. ncbi Changes in autophagic response in patients with chronic hepatitis C virus infection
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    Am J Pathol 178:2708-15. 2011
    ..Neither genotype nor viral load influenced the autophagy level. In conclusion, autophagy is altered in hepatocytes from CHC patients, likely due to a blockade of the last step of the autophagic process...
  42. ncbi Acute hepatitis E with severe jaundice: report of three cases
    Rami Moucari
    Hepatology Department and INSERM U773, CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Eur J Gastroenterol Hepatol 19:1012-5. 2007
    ..HEV-RNA detection by real-time reverse transcriptase-PCR is a very efficacious diagnostic tool in anti-HEV immunoglobulin-M-negative cases...
  43. ncbi Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy
    David Saadoun
    , Paris, France
    Arthritis Rheum 52:2917-25. 2005
    ..3 versus 5.3 +/- 3.4 for MIP-1alpha and 7.2 +/- 1.5 versus 2.5 +/- 0.9 for CXCR3). CONCLUSION: This study is the first to demonstrate a role of cellular immunity and Th1 lymphocytes in the pathogenesis of HCV-MC vasculitic nerve lesions...
  44. ncbi [Treatment of chronic hepatitis B.]
    Tarik Asselah
    , INSERM CRB3, , , Clichy (92
    Presse Med 35:327-34. 2006
    ..They induce a sustained response after withdrawal of therapy in only a minority of patients and therefore the treatment needs to be indefinitely administered in the majority of patients...
  45. ncbi [Chronic hepatitis C: what to do if the first treatment failed?]
    Tarik Asselah
    Service d Hepatologie, INSERM U481, Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, 92118 Clichy
    Gastroenterol Clin Biol 26:B50-9. 2002
  46. ncbi [Chronic hepatitis B: which patients should be treated and how?]
    Tarik Asselah
    Hepatologie, INSERM U481, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 29:374-83. 2005
  47. ncbi Multifactorial aetiology of hepatic infarction: a case report with literature review
    Sven Francque
    , , Clichy, France
    Eur J Gastroenterol Hepatol 16:411-5. 2004
    ..Because hepatic infarction is usually explained by the concurrence of several factors impairing the hepatic blood supply, an extensive search for associated conditions is necessary even when a conspicuous cause is present...
  48. ncbi The current status of antiviral therapy of chronic hepatitis B
    Tarik Asselah
    , Unioersity Paris 7, , AP-HP, Clichy, France
    J Clin Virol 34:S115-24. 2005
    ....
  49. ncbi [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]
    Rami Moucari
    Pôle des Maladies de l Appareil Digestif, Service d Hépatologie et INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 31:643-54. 2007
    ..Insulin resistance and steatosis, appear to be associated with fibrosis progression and impairment of sustained response to antiviral treatment...
  50. ncbi Long-term outcome of hepatitis C infection after bone marrow transplantation
    Regis Peffault De Latour
    Service d hématologie greffe de moelle, the Université Paris VII, Paris, France
    Blood 103:1618-24. 2004
    ..Systematic detection of HCV infection, liver biopsy, and therapeutic intervention are therefore warranted in long-term marrow transplant recipients...
  51. ncbi Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites
    Thomas Sersté
    Service d Hepatologie, Hôpital AP HP Beaujon, Clichy, France
    Liver Int 31:494-8. 2011
    ..The aim of this prospective study was to investigate the presence of bactDNA in AF and serum among cirrhotic outpatients with non-neutrocytic ascites...
  52. ncbi Fibrosis and disease progression in hepatitis C
    Patrick Marcellin
    Service d Hépatologie and INSERM U 481, Hopital Beaujon, Clichy, France
    Hepatology 36:S47-56. 2002
    ..Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis...
  53. ncbi CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients
    Vivien Beziat
    INSERM UMR S 945, Hopital Pitie Salpetriere, Paris, France
    Eur J Immunol 42:447-57. 2012
    ..Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection resulting in clonal expansion and differentiation of educated and polyfunctional NK cells...
  54. ncbi [Treatment of chronic hepatitis B]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:624-32. 2005
    ..However, one may expect that their use in monotherapy could not induce a high rate of sustained response and that long-term therapy or combination should be needed to improve efficacy and/or reduce resistance...
  55. ncbi Allogeneic hematopoietic cell transplant in HCV-infected patients
    Regis Peffault De Latour
    Service d Hématologie Greffe, Hopital Saint Louis, 75475 Paris, France
    J Hepatol 48:1008-17. 2008
    ..The pathophysiology of liver fibrosis is discussed as well as the present recommended therapy in this particular population...
  56. ncbi Mechanisms of non-response to antiviral treatment in chronic hepatitis C
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U955, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Clin Res Hepatol Gastroenterol 35:S31-41. 2011
    ..The goal of this review is to discuss mechanisms involved in the non-response to current and future standard treatments...
  57. ncbi The role of HBsAg quantification for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773, CRB3, Universite Paris Diderot, Hopital Beaujon, Clichy, France
    Liver Int 33:125-32. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy...
  58. ncbi Genomics and HCV infection: Progression of fibrosis and treatment response
    Emilie Estrabaud
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, BP 416, F 75018 Paris, France Université Denis Diderot Paris 7, site Bichat, BP 416, F 75018 Paris, France Service d Hépatologie, PMAD Hôpital Beaujon, 100 bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, France Electronic address
    J Hepatol 57:1110-25. 2012
    ..Recent findings on the IL-28B polymorphism and its application in clinical practice will also be discussed...
  59. ncbi Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst
    Sophie Buyse
    Fédération d Hépato Gastroentérologie et INSERM U481, Service de Radiologie, Service d Anatomie Pathologique, Service de Chirurgie viscérale and Service de Médecine Interne, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 16:1241-4. 2004
    ..The patient was treated with heparin. Surgical evacuation of the cyst using the 'fenestration' technique was also performed. There was no recurrent pulmonary embolism or hepatic cyst during a 1-year follow-up period...
  60. ncbi Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
    Ivan Bieche
    INSERM, UMR735, St Cloud, F 92210 Centre Renè Huguenin, FNCLCC, St Cloud, F 92211, France
    Pharmacogenet Genomics 17:731-42. 2007
    ....
  61. ncbi [Treatment of chronic hepatitis B]
    Tarik Asselah
    , INSERM U481, , 92110 Clichy
    Gastroenterol Clin Biol 28:1215-27. 2004
  62. ncbi Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response
    Emilie Estrabaud
    Service d Hépatologie and INSERM U773 CRB3, Beaujon Hospital, University Paris VII, France
    J Hepatol 55:1150-3. 2011
    ....
  63. ncbi Prolonged cholestasis and ductopenia associated with tenoxicam
    Viviane Trak-Smayra
    Department of Pathology, Beaujon Hospital, , 92118 Clichy Cedex, France
    J Hepatol 39:125-8. 2003
    ..and (3) the presence of ductopenia contrasted with the "clinical recovery" of the disease suggesting accessory bile drainage by cholangioles or partial reconstruction of the biliary tree...
  64. ncbi Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris VII, AP HP, CHU Beaujon, Clichy, France
    J Hepatol 48:200-7. 2008
    ..Mortality related to HCV and HBV infections was estimated in France...
  65. ncbi Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine
    Patrick Marcellin
    Service d Hepatologie, INSERM CRB3, University of Paris VII, Hopital Beaujon, Clichy, France
    Hepatol Res 37:S55-61. 2007
    ..PEG IFN, administered for 48 weeks, gives an overall sustained response rate of approximately 30%. Two large randomized controlled trials have conducted to registration of PEG IFN-alpha-2a in the treatment of chronic hepatitis B...
  66. ncbi Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study
    Bertrand Condat
    , , , AP-HP, Paris, France
    Hepatology 37:1302-8. 2003
    ..MR cholangiography coupled with MR portography is an effective noninvasive examination for simultaneous visualization of bile ducts and their relationship to the cavernoma...
  67. ncbi [What does chronic hepatitis C steatosis mean?]
    Tarik Asselah
    Gastroenterol Clin Biol 27:1073-5. 2003
  68. ncbi Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy
    Manuela G Neuman
    Division of Clinical Pharmacology, E 240, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    Cytokine 17:108-17. 2002
    ....
  69. ncbi Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean-Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre-les-Nancy, France
    Gastroenterology 131:1040-8. 2006
    ....
  70. ncbi Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C
    Bertrand Condat
    Service d Hepato Gastroenterologie, hôpital Saint Camille, Bry sur Marne, France
    Eur J Gastroenterol Hepatol 18:287-9. 2006
    ..Clinicians should be aware of this potential complication when evaluating the ratio benefit/risk of treatment in patients with chronic hepatitis C infection...
  71. ncbi Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
    Gioacchino Leandro
    IRCSS de Bellis, Castellana Grotte, Italy
    Gastroenterology 130:1636-42. 2006
    ..Hepatic inflammation may mediate fibrogenesis in patients with liver steatosis. Control of metabolic factors (such as overweight, via lifestyle adjustments) appears important in the management of CHC...
  72. ncbi Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B
    Patrick Marcellin
    J Hepatol 43:920-3. 2005